title: Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy.
abstract: OBJECTIVE
  To evaluate the effects of treatment on respiratory rate, serum natriuretic peptide concentrations, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure (CHF) secondary to degenerative mitral valve disease (MVD) and dilated cardiomyopathy (DCM).
  
  
  METHODS
  Prospective cohort study.
  
  
  METHODS
  63 client-owned dogs.
  
  
  METHODS
  Physical examination, thoracic radiography, analysis of natriuretic peptide concentrations, and Doppler echocardiography were performed twice, at baseline (examination 1) and 5 to 14 days later (examination 2). Home monitoring of respiratory rate was performed by the owners between examinations.
  
  
  RESULTS
  In dogs with MVD, resolution of CHF was associated with a decrease in respiratory rate, serum N-terminal probrain natriuretic peptide (NT-proBNP) concentration, and diastolic functional class and an increase of the ratio of peak velocity of early diastolic transmitral flow to peak velocity of early diastolic lateral mitral annulus motion (E:Ea Lat). In dogs with DCM, resolution of CHF was associated with a decrease in respiratory rate and serum NT-proBNP concentration and significant changes in 7 Doppler echocardiographic variables, including a decrease of E:Ea Lat and the ratio of peak velocity of early diastolic transmitral flow to isovolumic relaxation time. Only respiratory rate predicted the presence of CHF at examination 2 with high accuracy.
  
  
  CONCLUSIONS
  Resolution of CHF was associated with predictable changes in respiratory rate, serum NT-proBNP concentration, and selected Doppler echocardiographic variables in dogs with DCM and MVD. Home monitoring of respiratory rate was simple and was the most useful in the assessment of successful treatment of CHF.
authors.affiliation: Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA. schober.4@osu.edu
authors.forename: Karsten E
authors.initials: KE
authors.lastname: Schober
authors.forename: Taye M
authors.initials: TM
authors.lastname: Hart
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Stern
authors.forename: Xiaobai
authors.initials: X
authors.lastname: Li
authors.forename: Valerie F
authors.initials: VF
authors.lastname: Samii
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Zekas
authors.forename: Brian A
authors.initials: BA
authors.lastname: Scansen
authors.forename: John D
authors.initials: JD
authors.lastname: Bonagura
mesh_terms: D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000662:veterinary*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D015331:Cohort Studies; D004283:Dog Diseases / Q000188:drug therapy; D004285:Dogs; D015150:Echocardiography, Doppler / Q000662:veterinary*; D006333:Heart Failure / Q000188:drug therapy / Q000662:veterinary*; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000662:veterinary*; D045265:Natriuretic Peptides / Q000097:blood*; D012119:Respiration / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents; D045265:Natriuretic Peptides